Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Ruxolitinib

2

XVII.y Cryptococcus pulmonary and/or systemic infection

1
Last update : 26/10/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Ruxolitinib dicontinuation/withdrawal
1

Publications

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis.
Respiratory medicine case reports 2017;22;87-90 2017
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Chest 2013 May;143;1478-1479 2013 May

Powered by

  • ^
  • Contact
  • Cookies
  • About